Roberto Cemin

TL;DR: In a multicenter, double-blind trial, eligible adults with acute pericarditis were randomly assigned to receive either colchicine (at a dose of 0.5 mg twice daily for 3 months for patients weighing >70 kg or placebo in addition to conventional antiinflammatory therapy with aspirin or ibuprofen as discussed by the authors.

TL;DR: In this article, the authors evaluated the efficacy and safety of colchicine for the secondary prevention of recurrent pericarditis in 120 patients with a first recurrence of pericharditis.

TL;DR: It is suggested that colchicine should be probably regarded as a first-line treatment for either acute or recurrent pericarditis in the absence of contraindications or specific indications.

TL;DR: Among patients undergoing cardiac surgery, perioperative use of colchicine compared with placebo reduced the incidence of postpericardiotomy syndrome but not of postoperative AF or postoperative pericardial/pleural effusion.

TL;DR: In this article, the authors used colchicine for the prevention of post-pericardiotomy syndrome (PPS) and post-operative atrial fibrillation (POAF) after cardiac surgery.